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Diabetic nephropathy (DN) is an important long-term com-
plication of diabetes. DN is now the most common cause
of end-stage renal disease (ESRD) in many countries [1].
Both the increasing prevalence of type 2 DM and increased
acceptance of diabetic patients into renal replacement ther-
apy (RRT) programmes have contributed to this. Indeed,
there has been a marked increase in the incidence of renal
replacement therapy (RRT) for type 2 DM over time [1]. DN
is also a major burden on health care budgets [2] and is
associated with a reduction in health-related quality of life [3,
4]. Moreover, DN is associated with increased cardiovascular
mortality in both type 1 and type 2 diabetic patients [5, 6].
Only a proportion of patients with DN progress to ESRD,
and even in those who do progress, there is a long lag time
between onset of DN and progression to ESRD. What is
therefore needed is early diagnosis of DN and safe effective
therapy which halts or slows down its progression as well
as therapy which reduces the risk of adverse cardiovascular
events in DN patients. The development of regenerative
medicine for the cure of renal disease is another goal, which
does not seem to be within our reach in the near future.
Diabetic nephropathy is associated with typical histolog-
ical features. The Renal Pathology Society has proposed a
histopathological classification of diabetic nephropathy [7]. It
is hoped that this new classification might be useful in better
staging of the disease and in stratifying risk. However, a renal
biopsy is not indicated in the majority of cases.
The diagnosis of diabetic renal disease, therefore, usually
relies on measuring the urinary albumin excretion rate and
the glomerular filtration rate (GFR) and on exclusion of other
causes of renal disease. Whilst an elevation in the urinary
albumin excretion rate is often the earliest sign of DN, mea-
surement of glomerular filtration is increasingly important
as the disease progresses. Previously, serum creatinine alone
was used as a maker of GFR. A long recognised problem of
using serum creatinine as a measure of filtration function is
that the GFR can fall to a clinically significant level before the
creatinine level in the serum begins to rise—there being an
inverse reciprocal relationship between serum creatinine and
GFR.The laboratory measurement of serum creatinine using
the Jaffe method has resulted in interlaboratory variability
and more recently clinical chemistry laboratories have been
restandardising assays against an isotope mass spectrometry
method. Whilst serum creatinine levels are influenced by
GFR, they are also related to muscle mass and other static
and changing parameters. During the last decade many
laboratories have reported estimated GFR (eGFR) using a
variety of calculated formulae based on parameters including
age, race, gender, creatinine (see above), and in some cases
urea and albumin. The reporting of eGFRs was designed
to identify those with modest degrees of renal impairment
that may have been missed by clinicians relying on serum
creatinine alone. The commonly used formulae for eGFRs,
such as Cockcroft Gault and the Modification of Diet in
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Renal Disease (MDRD) formulae, are inaccurate at GFR
levels above 60mL/min, so many laboratories will not report
specific levels above 60mL/min and will simply report a
value >60mL/min in this cohort. There are a number of
circumstances where eGFR estimates are not valid includ-
ing the presence of amputations, skeletal muscle diseases,
extremes of age, and extremes of weight, pregnancy, and
paraplegia and rapid changes in filtration function.These are
often not appreciated by clinicians reviewing results on their
patients.Thewidespread introduction of eGFRmeasurement
has revealed many patients with eGFRs in the 30–40mL/min
range resulting in an increased rate of referral to renal
departments. Whether this has resulted in clinical benefit is
debatable. How much benefit have we derived from eGFR
measurements?
E. Y. Lee et al. in one of the papers in this issue have
compared two formulae commonly used to estimate GFR,
namely, the MDRD and the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) in type 2 patients with
DN in Korea. They conclude that the CKD-EPI formula
may more accurately stratify chronic kidney disease (CKD)
in those with type 2 diabetes compared to the MDRD
equation. However, this finding needs to be contrasted with
the findings from the paper by X. Liu et al. which investigates
the performance of the various formulas used to estimate
GFR. They conclude that none of the 8 formulae examined
in Chinese type 2 diabetic subjects had sufficient accuracy
compared to an isotopic measurement of GFR. Inspection
of the Bland Altman plots in this paper starkly demonstrates
the wide levels of bias and the very wide levels of agreement
between the eGFRs and standard GFR. One important point
that has to be stressed is that there may be racial differ-
ences in the performance of various formulas to estimate
GFR.
So what should clinicians take from these and other stud-
ies investigating eGFR equations? Firstly, they are “estimates”
of the GFR in the same way that serum creatinine is an
estimate and adding more parameters does not necessarily
increase the accuracy. Secondly, they are likely to be inaccu-
rate if the GFR exceeds 60mL/min. Thirdly, there are many
situations where they are likely to be particularly inaccurate
and this includes using a certain formula derived from one
racial group being applied in a different racial cohort.
Another area of research is the search for possible
biomarkers of diabetic nephropathy. These may be useful in
the diagnosis or in predicting prognosis in terms of progres-
sion or of cardiovascular complications.These include the use
of proteomics, newmarkers of renal dysfunction, and micro-
RNAs. The latter are short noncoding RNAs that may have
regulatory roles. In another paper appearing in this issue,
R. Li et al. review the possible role of micro-RNAs in the
pathogenesis of DN and as potential biomarkers.
Although blood pressure control and blockade of the
renin-angiotensin-aldosterone system are well-established as
effective therapies in reducing the rate of progression of
diabetic renal disease, there is still a large unmet need in the
developing new treatment modalities. Research has focused
on finding agents which inhibit molecules or key steps in
pathways thought to be important in the pathogenesis of
diabetic nephropathy, such as the polyol pathway and trans-
forming growth factor-𝛽. Unfortunately, these avenues have,
to date, been largely unsuccessful in providing the clinician
with new therapeutic tools. In separate papers appearing in
this issue, two novel therapies, namely, resveratrol (F. Xu et
al.) and L-arginine (T. Claybaugh et al.), are investigated in
animal models.The review paper by Li et al. appearing in this
special issue also discusses the potential role of micro-RNAs
as novel therapeutic modalities.
Stephen Fava
Samy Hadjadj
James Walker
References
[1] P. C. W. Van Dijk, K. J. Jager, B. Stengel, C. Gro¨nhagen-Riska,
T. G. Feest, and J. D. Briggs, “Renal replacement therapy for
diabetic end-stage renal disease: data from 10 registries in
Europe (1991–2000),” Kidney International, vol. 67, no. 4, pp.
1489–1499, 2005.
[2] R. N. Foley and A. J. Collins, “The growing economic burden of
diabetic kidney disease,” Current Diabetes Reports, vol. 9, no. 6,
pp. 460–465, 2009.
[3] A. J. Ahola,M. Saraheimo,C. Forsblom,K.Hietala,H. Sintonen,
and P. Groop, “Health-related quality of life in patients with
type 1 diabetes-association with diabetic complications (the
FinnDiane Study),”Nephrology Dialysis Transplantation, vol. 25,
no. 6, pp. 1903–1908, 2010.
[4] H. C. Park, H.-B. Yoon,M.-J. Son et al., “Depression and health-
related quality of life in maintenance hemodialysis patients,”
Clinical Nephrology, vol. 73, no. 5, pp. 374–380, 2010.
[5] G. Bruno, F. Merletti, A. Biggeri et al., “Fibrinogen and AER
are major independent predictors of 11-year cardiovascular
mortality in type 2 diabetes: the Casale Monferrato Study,”
Diabetologia, vol. 48, no. 3, pp. 427–434, 2005.
[6] K. V. Allen and J. D. Walker, “Microalbuminuria and mortality
in long-duration type 1 diabetes,” Diabetes Care, vol. 26, no. 8,
pp. 2389–2391, 2003.
[7] T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic
classification of diabetic nephropathy,” Journal of the American
Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010.
View publication stats
